Our Rx Vigilance™ product consists of unique statistical, epidemiological, and clinical analyses of spontaneous adverse event data reported to the FDA and the World Health Organization (WHO) for marketed products. Among the many features of Rx Vigilance™, clients gain the capacity to:
- Forecast negative FDA safety actions before they occur
- Compare the safety-efficacy profiles between new drugs and competitor drugs
- Identify the presence of rare adverse events of new products
We produce Rx Vigilance™ in collaboration with industry partners, using post-marketing safety surveillance techniques and quantitative inferential modeling based on complex mapping, algorithms and statistical tools.